Modern concepts on the use of antiangiogenic drugs as adjuvant therapy in neovascular glaucoma
https://doi.org/10.25700/NJG.2021.01.07
Abstract
The article analyzes literature data on the use of modern antiangiogenic drugs in the treatment of neovascular glaucoma (NVG) presenting information on the mechanisms of action of inhibitors of vascular endothelial growth factor (VEGF) as adjuvant therapy in NVG, as well as the clinical effectiveness of these drugs in modulating the activity of ocular tissue healing processes after surgical treatment of glaucoma.
The article also considers the results of studies on the use of VEGF inhibitors bevacizumab, ranibizumab, and aflibercept by different routes of administration. Usage of these drugs is indicated to require taking into account the contraindications, as well as the possibility of side effects associated with the intravitreal route of drug administration. The effects of anti-VEGF drugs in the treatment of NVG have been noted to be temporary and last 4–6 weeks, so the result of using a combination of these drugs and standard methods of treating the disease is assumed to be more pronounced and lasting.
About the Authors
E. V. Belousova
S.N. Fedorov National Medical Research Center "MNTK "Eye Microsurgery"
Russian Federation
Russian Federation
Cand. Sci. (Med.), Junior Researcher of the Glaucoma Surgery Department
59A Beskudnikovsky Blvd., Moscow, 127486
T. V. Sokolovskaya
S.N. Fedorov National Medical Research Center "MNTK "Eye Microsurgery"
Russian Federation
Russian Federation
Cand. Sci. (Med.), Leading Researcher of the Glaucoma Surgery Department
59A Beskudnikovsky Blvd., Moscow, 127486
N. M. Kislitsyna
S.N. Fedorov National Medical Research Center "MNTK "Eye Microsurgery"
Russian Federation
Russian Federation
Cand. Sci. (Med.), Ophthalmologist at the Department of Vitreoretinal Surgery and Diabetes of the Eye
59A Beskudnikovsky Blvd., Moscow, 127486
References
1. Rykov S.A., Novak N.V. The effectiveness of the combined method of surgical treatment of secondary neovascular glaucoma. Oftal'mologiya. Vostochnaya Evropa. 2018; 8(2):206-211. (In Russ.)
2. Babushkin A.E. On the treatment of neovascular glaucoma. Point of view. Vostok – Zapad. 2019; 2:120-123. (In Russ.) doi:10.25276/2410-1257-2019-2-120-123
3. Zotov A.S., Efremova T.G., Nesterova E.S., Solodkova E.G., Balalin S.V. The use of angiogenesis inhibitors in the complex treatment of neovascular glaucoma. Sovremennye tekhnologii v oftal'mologii. 2019; 4(29):108-111. (In Russ.) doi:10.25276/2312-4911-2019-4-108-111
4. Karpilova M.A., Durzhinskaya M.Kh. Anti-VEGF-drugs in the treatment of neovascular glaucoma. Bulletin of Ophthalmology. 2019; 135(5-2):299-304. (In Russ.) doi:10.17116/oftalma2019135052299
5. Sun C., Zhang H., Jiang J., Li Y., Nie C., Gu J., Luo L., Wang Z. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2019 Dec 4. doi:10.1007/s10792-019-01207-4
6. Du J., Patrie J.T., Prum B.E., Netland P.A., Shildkrot Y.E. Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019; 28(12):1035-1040. doi:10.1097/IJG.0000000000001382
7. Chen H.J., Ma Z.Z., Li Y., Wang C.G. Change of Vascular Endothelial Growth Factor levels following vitrectomy in eyes with proliferative diabetic retinopathy. J Ophthalmol. 2019; Oct 23;2019:6764932. doi:10.1155/2019/6764932
8. Sun C., Zhang H.S., Yan Y.J., Zhao T., Li A.H., Tang Y., Wang Z.J. Early vitrectomy combined with pan retinal photocoagulation, antivascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma. Chin Med J (Engl). 2019; 132(20):2518-2520. doi:10.1097/CM9.0000000000000482
9. Rong A.J., Swaminathan S.S., Vanner E.A., Parrish R.K. 2nd. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019; 204:62-69. doi:10.1016/j.ajo.2019.02.038
10. Sakamoto M., Hashimoto R., Yoshida I., Ubuka M., Maeno T. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clin Ophthalmol. 2018; 12:2323-2329. doi:10.2147/OPTH.S184959.
11. Seibold L.K., Sherwood M.B., Kahook M.Y. Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530–550. doi:10.1016/j.survophthal.2012.01.008
12. Saeedi O.J., Jefferys J.L., Solus J.F., Jampel H.D., Quigley H.A. Risk factors for adverse consequences of low intraocular pressure after trabeculectomy. J Glaucoma. 2014; 23(1):e60–8. doi:10.1097/IJG.0000000000000008
13. Daneshvar R. Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res. 2013; 8(2):182–186. PMID: 23943695
14. Park S.C., Su D., Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012; 12(12):1641–1647. doi:10.1517/14712598.2012.721772
15. SooHoo J.R., Seibold L.K., Kahook M.Y. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28(3):165–172. doi:10.3109/08820538.2012.730103
16. Kim M., Lee C., Payne R., Yue B.Y., Chang J.H., Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol. 2015; 60(6):524–535. doi:10.1016/j.survophthal.2015.04.003
17. Kitnarong N., Sriyakul C., Chinwattanakul S. A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther. 2015; 4(1):33–41. doi:10.1007/s40123-015-0033-3
18. SooHoo J.R., Seibold L.K., Pantcheva M.B., Kahook M.Y. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015; 43(9):803–807. doi:10.1111/ceo.12559
19. Magdelaine-Beuzelin C., Pinault C., Paintaud G., Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2010; 2(2):176–180. doi:10.4161/mabs.2.2.11205
20. Simha A., Braganza A., Abraham L., Samuel P., Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013; 10:CD007920. doi:10.1002/14651858
21. Waisbourd M., Shemesh G., Kurtz S., Rachmiel R., Moisseiev E., ZayitSoudri S., Loewenstein A., Barequet I. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014; 93(3-4): 108–112. doi:10.1159/000358600
22. Duch S., Buchacra O., Milla E., Andreu D., Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009; 18(2):140–143. doi:10.1097/IJG.0b013e318170a747
23. Luke J., Nassar K., Luke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10):2403–2413. doi:10.1007/s00417-013-2428-y
24. Grover S., Gupta S., Sharma R., Brar V.S., Chalam K.V. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009; 93(2):273–274. doi:10.1136/bjo.2008.145714
25. Sugimoto Y., Mochizuki H., Okumichi H., Takumida M., Takamatsu M., Kawamata S., Kiuchi Y. et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1601–1609. doi:10.1007/s00417-010-1406-x
26. Muhsen S., Compan J., Lai T., Kranemann C., Birt C. Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma. Int J Ophthalmol. 2019; 12(10):1567-1574. doi:10.18240/ijo.2019.10.08
27. Elwehidy A.S., Bayoumi N.H., Badawi A.E., Hagras S.M., Abdelkader A. Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila). 2019; 8(4):308-313. doi:10.1097/APO.0000000000000248
28. Li Z., Van Bergen T., Van de Veire S., Van de Vel I., Moreau H., Dewerchin M., Maudgal P.C., Zeyen T., Spileers W., Moons L., Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009; 50(11):5217–5225. doi:10.1167/iovs.08-2662
29. Memarzadeh F., Varma R., Lin L.T., Parikh J.G., Dustin L., Alcaraz A., Eliott D. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009; 50(7):3233–3237. doi:10.1167/iovs.08-2441
30. Ozgonul C., Mumcuoglu T., Gunal A. The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res. 2014; 39(5):451–459. doi:10.3109/02713683.2013.851704
31. Sengupta S., Venkatesh R., Ravindran R.D. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma. 2012; 21(7):450–459. doi:10.1097/IJG.0b013e31821826b2
32. Tai T.Y., Moster M.R., Pro M.J., Myers J.S., Katz L.J. Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma. 2015; 24(4):311–315. doi:10.1097/IJG.0b013e31829f9bd3
33. Pro M.J., Freidl K.B., Neylan C.J., Sawchyn A.K., Wizov S.S., Moster M.R. Ranibizumab versus mitomycin C in primary trabeculectomy — a pilot study. Curr Eye Res. 2015; 40(5):510–515. doi:10.3109/02713683.2014.935441
34. Nilforushan N., Yadgari M., Kish S.K., Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012; 153(2):352–7.e1. doi:10.1016/j.ajo.2011.08.005
35. Akkan J.U., Cilsim S. Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma. 2015; 24(1):1–8. doi:10.1097/IJG.0b013e318287abf3
36. Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(10):4807–13. doi:10.1167/iovs.08-3148
37. Jurkowska-Dudzinґska J., Kosior-Jarecka E., Zarnowski T. Comparison of the use of 5-flfluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Exp Ophthalmol. 2012; 40(4):e135– 42. doi:10.1111/j.1442-9071.2011.02608.x
38. Vandewalle E., Abegão Pinto L., Van Bergen T., Spielberg L., Fieuws S., Moons L., Spileers W., Zeyen T., Stalmans I. et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014; 98(1):73–78. doi:10.1136/bjophthalmol-2013-303966
39. Hau S., Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol. 2009; 20(2):131–136. doi:10.1097/ICU.0b013e328325a54b
40. Yoeruek E., Spitzer M.S., Tatar O., Aisenbrey S., Bartz-Schmidt K.U., Szurman P. Safety profifile of bevacizumab on cultured human corneal cells. Cornea. 2007; 26(8):977–982. doi:10.1097/ICO.0b013e3180de1d0a
41. Bochmann F., Kaufmann C., Becht C.N., Guber I., Kaiser M., Bachmann L.M., Thiel M.A. et al. ISRCTN12125882-inflfluence of topical anti-VEGF Ranibizumab) on the outcome of filtration surgery for glaucoma-study protocol. BMC Ophthalmol. 2011; 11:1. doi:10.1186/1471-2415-11-1
42. Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005; 118(Pt 16):3759–68. doi:10.1242/jcs.02483
43. Liu X., Du L., Li N. The effects of bevacizumab in augmenting trabeculectomy for glaucoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(15):e3223. doi:10.1097/MD.0000000000003223
Review
For citations:
Belousova E.V., Sokolovskaya T.V., Kislitsyna N.M. Modern concepts on the use of antiangiogenic drugs as adjuvant therapy in neovascular glaucoma. National Journal glaucoma. 2021;20(1):55-64. (In Russ.) https://doi.org/10.25700/NJG.2021.01.07
Views:
493
Email this article 